Science Delphia Therapeutics
Breakthrough research has revealed that many oncogenic pathways are also highly vulnerable to overactivation. Too much pathway activation can actually drive lethal cellular stress (“activation lethality”).
delphiatx.comCrawled Nov 2, 2026
Breakthrough research has revealed that many oncogenic pathways are also highly vulnerable to overactivation. Too much pathway activation can actually drive lethal cellular stress (“activation lethality”).
Delphia uses its activation lethality platform to develop targeted cancer medicines addressing oncogene overactivation.
Alexis Borisy has 30 years of experience founding, operating, and investing in science-based companies.
Dan Lynch advises life sciences CEOs and executives as an executive venture partner at GV.
Dr. David Schenkein has worked as a physician and in drug development to improve patient and family outcomes.
Dr. Kevin Marks leads Delphia as president, CEO, and board member, with two decades of cancer drug development experience.
Dr. Mike Dillon leads drug discovery at a biotech company with over 30 years of experience in pharma and biotech.
Dr. William Sellers directs the cancer program at the Broad Institute and teaches at Dana-Farber Cancer Institute and Harvard.
Delphia is pioneering an entirely new field of cancer biology - activation lethality - to advance a new treatment paradigm and improve the lives of cancer patients.
Delphia is pioneering activation lethality - a next-generation precision medicine approach that targets cancer's surprising vulnerability to oncogene overactivation.
Delphia Therapeutics names **David P. Kerstein, M.D.** as its new **Chief Medical Officer**. He joins the biopharmaceutical company specializing in **activation lethality**, a cancer therapy approach targeting vulnerabilities from oncogene overactivation. Kerstein’s background includes leadership in **oncology drug development**, spanning early- to late-stage precision oncology programs.
Delphia Therapeutics adds Stephen (Steve) Kelsey, M.D., a physician-scientist and oncologist, to its board of directors. Kelsey specializes in cancer drug development and currently leads research initiatives as president of a major institution. The biopharmaceutical company focuses on targeting cancer’s vulnerability to oncogene overactivation through its activation lethality platform.
Delphia Therapeutics names Reza Mazhari, Ph.D., as its new Chief Business Officer. Mazhari joins the biopharmaceutical company with over 20 years of experience in oncology drug discovery, clinical development, and business development. Delphia focuses on targeting cancer’s vulnerability to oncogene overactivation, a novel approach in cancer biology.
Delphia launched a novel cancer therapeutic approach called **Activation Lethality** after emerging from stealth in **May 2024**. The company introduces a precision medicine method distinct from existing treatments, targeting tumors with a mechanism designed to selectively induce cell death. Delphia’s model combines diagnostic and therapeutic capabilities to personalize cancer care beyond conventional methods.
Delphia Therapeutics secures **$67 million in Series A funding** to advance a novel cancer treatment approach. The company develops drugs designed to **over-activate oncogene pathways**, triggering cancer cell death. This mechanism targets tumors by exploiting their own genetic vulnerabilities.
Delphia Therapeutics secures $67 million in funding to develop cancer therapies that overactivate key cancer drivers, diverging from traditional approaches targeting inhibition. The company focuses on activating pathways to spur tumor cell destruction. Founded by experienced biotech leaders, Delphia aims to pioneer a new class of precision oncology treatments.
Delphia Therapeutics launches to develop cancer therapies based on **activation lethality**, targeting tumors driven by oncogene overactivation. The company secures **$67 million in funding** from leading oncology drug developers to advance this approach. This strategy exploits cancer cells' reliance on excessive oncogene activity, offering a potential new treatment avenue.
Delphia Therapeutics introduces a novel cancer treatment strategy called **activation lethality**, targeting tumors by exploiting their vulnerability to oncogene overactivation. The company develops next-generation therapies designed to trigger cancer cell destruction through this mechanism. This approach represents a distinct field in oncology, focusing on how excessive oncogene activity can be weaponized against tumors.